FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992044492> ?p ?o ?g. }

• W1992044492 endingPage "609" @default.
• W1992044492 startingPage "600" @default.
• W1992044492 abstract "Haemoglobin based oxygen carriers (HBOCs) are considered in the treatment of patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In light of their potential vasopressor and colloidal properties, their effect on coronary physiology, safety and tolerability needs to be established.In this phase II pilot trial, 45 patients were randomly assigned, (1:1:1) to double blind treatment with a 30 minute intravenous (IV) infusion of either 15 or 30 g of HBOC-201, compared to an equivalent volume of non-oxygen carrier colloid control. Systemic, pulmonary, and coronary haemodynamics were studied during this infusion period. IV HBOC-201 administration produced an increase in systolic blood pressure (SBP), pulmonary capillary wedge pressure and calculated systemic vascular resistance (SVR) and a concomitant decrease in cardiac output (CO); there was a decrease in mixed venous saturation (SVO2) following IV HBOC-201. The left ventricular stroke work index (LVSWI) was not altered by HBOC-201 treatment. Of note, no coronary vasoconstriction was observed, nor were there significant changes in resting average peak velocity (APV), coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. The percentage of patients with adverse events did not differ between the HBOC-201 treated and control groups (76% vs. 63%, respectively, P=0.49). Seven serious adverse events (SAE) occurred in six patients in the treatment group and two in two patients in the control group. Only one SAE (hypertension) was judged HBOC-201 related. Patients in both the HBOC-201 and control group had a similar incidence of increased liver alanine transaminase (31% vs 31%, respectively, NS); 10% of the patients in the HBOC-201 group had increases greater than three times the upper limit of normal. Differential increases were noticed in some inflammatory markers (IL-6, CRP) 18-24 hours after infusion between the HBOC-201 arms and the control group.No compromise in the coronary blood flow or LVSWI was observed despite HBOC-201's known vasoactive effects. One SAE was adjudicated as drug related and fully resolved. The clinical relevance of the differential rise in certain biochemical markers and the adverse effects of plasma haemoglobin in the context of ACS needs further investigation." @default.
• W1992044492 created "2016-06-24" @default.
• W1992044492 creator A5017938107 @default.
• W1992044492 creator A5054452062 @default.
• W1992044492 creator A5057178455 @default.
• W1992044492 creator A5059011787 @default.
• W1992044492 creator A5062242310 @default.
• W1992044492 creator A5063096193 @default.
• W1992044492 creator A5063792624 @default.
• W1992044492 creator A5070132690 @default.
• W1992044492 creator A5074210894 @default.
• W1992044492 creator A5076694709 @default.
• W1992044492 creator A5082002228 @default.
• W1992044492 date "2008-03-01" @default.
• W1992044492 modified "2023-10-16" @default.
• W1992044492 title "Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD" @default.
• W1992044492 cites W2002074235 @default.
• W1992044492 cites W2005415125 @default.
• W1992044492 cites W2007683284 @default.
• W1992044492 cites W2020590919 @default.
• W1992044492 cites W2044065144 @default.
• W1992044492 cites W2056430073 @default.
• W1992044492 cites W2061458010 @default.
• W1992044492 cites W2067026090 @default.
• W1992044492 cites W2072877187 @default.
• W1992044492 cites W2078057998 @default.
• W1992044492 cites W2081978633 @default.
• W1992044492 cites W2086406624 @default.
• W1992044492 cites W2091914310 @default.
• W1992044492 cites W2102297330 @default.
• W1992044492 cites W2132742512 @default.
• W1992044492 cites W2134956122 @default.
• W1992044492 cites W2138892332 @default.
• W1992044492 cites W2150027863 @default.
• W1992044492 cites W2153259204 @default.
• W1992044492 doi "https://doi.org/10.4244/eijv3i5a108" @default.
• W1992044492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19608488" @default.
• W1992044492 hasPublicationYear "2008" @default.
• W1992044492 type Work @default.
• W1992044492 sameAs 1992044492 @default.
• W1992044492 citedByCount "37" @default.
• W1992044492 countsByYear W19920444922012 @default.
• W1992044492 countsByYear W19920444922013 @default.
• W1992044492 countsByYear W19920444922014 @default.
• W1992044492 countsByYear W19920444922015 @default.
• W1992044492 countsByYear W19920444922016 @default.
• W1992044492 countsByYear W19920444922017 @default.
• W1992044492 countsByYear W19920444922019 @default.
• W1992044492 countsByYear W19920444922020 @default.
• W1992044492 countsByYear W19920444922021 @default.
• W1992044492 countsByYear W19920444922022 @default.
• W1992044492 crossrefType "journal-article" @default.
• W1992044492 hasAuthorship W1992044492A5017938107 @default.
• W1992044492 hasAuthorship W1992044492A5054452062 @default.
• W1992044492 hasAuthorship W1992044492A5057178455 @default.
• W1992044492 hasAuthorship W1992044492A5059011787 @default.
• W1992044492 hasAuthorship W1992044492A5062242310 @default.
• W1992044492 hasAuthorship W1992044492A5063096193 @default.
• W1992044492 hasAuthorship W1992044492A5063792624 @default.
• W1992044492 hasAuthorship W1992044492A5070132690 @default.
• W1992044492 hasAuthorship W1992044492A5074210894 @default.
• W1992044492 hasAuthorship W1992044492A5076694709 @default.
• W1992044492 hasAuthorship W1992044492A5082002228 @default.
• W1992044492 hasConcept C126322002 @default.
• W1992044492 hasConcept C146556889 @default.
• W1992044492 hasConcept C164705383 @default.
• W1992044492 hasConcept C178853913 @default.
• W1992044492 hasConcept C197934379 @default.
• W1992044492 hasConcept C2776779939 @default.
• W1992044492 hasConcept C2778375690 @default.
• W1992044492 hasConcept C2780400711 @default.
• W1992044492 hasConcept C42219234 @default.
• W1992044492 hasConcept C45393284 @default.
• W1992044492 hasConcept C500558357 @default.
• W1992044492 hasConcept C58245268 @default.
• W1992044492 hasConcept C71924100 @default.
• W1992044492 hasConcept C84393581 @default.
• W1992044492 hasConceptScore W1992044492C126322002 @default.
• W1992044492 hasConceptScore W1992044492C146556889 @default.
• W1992044492 hasConceptScore W1992044492C164705383 @default.
• W1992044492 hasConceptScore W1992044492C178853913 @default.
• W1992044492 hasConceptScore W1992044492C197934379 @default.
• W1992044492 hasConceptScore W1992044492C2776779939 @default.
• W1992044492 hasConceptScore W1992044492C2778375690 @default.
• W1992044492 hasConceptScore W1992044492C2780400711 @default.
• W1992044492 hasConceptScore W1992044492C42219234 @default.
• W1992044492 hasConceptScore W1992044492C45393284 @default.
• W1992044492 hasConceptScore W1992044492C500558357 @default.
• W1992044492 hasConceptScore W1992044492C58245268 @default.
• W1992044492 hasConceptScore W1992044492C71924100 @default.
• W1992044492 hasConceptScore W1992044492C84393581 @default.
• W1992044492 hasIssue "5" @default.
• W1992044492 hasLocation W19920444921 @default.
• W1992044492 hasLocation W19920444922 @default.
• W1992044492 hasOpenAccess W1992044492 @default.
• W1992044492 hasPrimaryLocation W19920444921 @default.
• W1992044492 hasRelatedWork W1977637730 @default.
• W1992044492 hasRelatedWork W2079494746 @default.

• next